Treatment of chronic hepatitis B

J Viral Hepat. 1994;1(2):105-24. doi: 10.1111/j.1365-2893.1994.tb00110.x.

Abstract

Chronic infection with the hepatitis B virus (HBV) is a major cause of worldwide morbidity and mortality. A large number of therapeutic approaches has been tried, including interferon (IFN), nucleoside analogues and immunomodulators. To date controlled clinical trials have shown that only IFN is of long-term value but many patients fail to respond to treatment. New approaches to treating patients with IFN-resistant hepatitis B are currently undergoing clinical and experimental evaluation, and it seems likely that new therapeutic agents will be available in the near future.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • Chronic Disease
  • Hepatitis B / therapy*
  • Hepatitis B e Antigens / immunology
  • Humans
  • Interferons / adverse effects
  • Interferons / therapeutic use
  • Levamisole / therapeutic use

Substances

  • Antiviral Agents
  • Hepatitis B e Antigens
  • Levamisole
  • Interferons